Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Organised by The MDS Foundation, the International Congress on Myelodysplastic Syndromes (MDS 2021) will take place from 23-26 September 2021 as a virtual event. VJHemOnc are pleased to be an official media partner with the MDS Foundation for the International Congress.

MDS 2021

23–26 September 2021 | Virtual Meeting

MDS 2021

23–26 September 2021 | Virtual Meeting
Organised by The MDS Foundation, the International Congress on Myelodysplastic Syndromes (MDS 2021) will take place from 23-26 September 2021 as a virtual event. VJHemOnc are pleased to be an official media partner with the MDS Foundation for the International Congress.
Update on lenalidomide for MDS 7:32
Update on lenalidomide for MDS
Valeria Santini • 23 Sep 2021
Novel targets in low-risk MDS 1:27
Novel targets in low-risk MDS
Sophie Park • 22 Sep 2021
Assessing response to ESAs and alternative therapies 5:25
Assessing response to ESAs and alternative therapies
Sophie Park • 22 Sep 2021
ESAs for the management of lower-risk MDS 2:37
ESAs for the management of lower-risk MDS
Sophie Park • 22 Sep 2021
Key advances in MDS management 1:22
Key advances in MDS management
Sandra Kurtin • 22 Sep 2021
The role of immune checkpoint inhibitors in MDS 4:27
The role of immune checkpoint inhibitors in MDS
Shahram Kordasti • 22 Sep 2021
Improving our understanding of MDS for better disease management 2:27
Improving our understanding of MDS for better disease management
Sandra Kurtin • 22 Sep 2021
Inflammatory signaling in the pathogenesis of MDS 3:19
Inflammatory signaling in the pathogenesis of MDS
David Sallman • 14 Sep 2021
SF3B1 mutant MDS 2:24
SF3B1 mutant MDS
David Sallman • 14 Sep 2021
Immunotherapy in MDS 4:44
Immunotherapy in MDS
David Sallman • 14 Sep 2021
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML 2:58
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML
Thomas Cluzeau • 20 Sep 2021
Integrated approaches to the diagnosis of MDS & MPNs 2:40
Integrated approaches to the diagnosis of MDS & MPNs
Anne Tierens • 16 Sep 2021
Optimizing transfusion support in MDS 3:02
Optimizing transfusion support in MDS
Yulia Lin • 17 Sep 2021
Classification of high-risk mutations in MDS 10:18
Classification of high-risk mutations in MDS
Moshe Mittelman • 13 Sep 2021
Clinical targets for successful iron chelation therapy 2:08
Clinical targets for successful iron chelation therapy
Heather Leitch • 15 Sep 2021
The immune system’s role in higher-risk MDS 6:05
The immune system’s role in higher-risk MDS
Shahram Kordasti • 22 Sep 2021

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals